Treat FTD Fund
The Treat FTD Fund supports early-stage clinical trials of innovative drugs or devices to advance biomarkers and therapies for frontotemporal degeneration (FTD).
Funder: Alzheimer's Drug Discovery Foundation
Due Dates: November 9, 2018 (Letter of Intent) | February 15, 2019 (Invited Full Proposal) | June 1, 2026 (Full Proposal)
Funding Amounts: Up to $2,500,000 over 1–3 years; typical awards range from $500,000–$2,000,000.
Summary: Supports early-stage clinical trials of drugs or devices for frontotemporal degeneration (FTD), advancing understanding, biomarkers, and therapies.
Description
The Treat FTD Fund is a joint initiative of the Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD), designed to accelerate the development of novel or repurposed therapeutics and devices for frontotemporal degeneration (FTD) disorders. The fund addresses the unique challenges of FTD drug development by supporting early/mid-stage clinical trials, trial readiness activities, and projects with strong scientific rationale and clear hypotheses. Emphasis is placed on innovative trial designs, patient-relevant outcomes, the use of informative biomarkers, and data sharing to advance the field. Both disease-modifying and symptomatic interventions are eligible, with a focus on approaches applicable to both genetic and sporadic forms of FTD.
